Identification
- Summary
Flutamide is an antiandrogen used for locally confined stage B2-C and D-2 metastatic prostate carcinoma.
- Brand Names
- Eulexin
- Generic Name
- Flutamide
- DrugBank Accession Number
- DB00499
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Flutamide (DB00499)
- Weight
- Average: 276.2118
Monoisotopic: 276.072176843 - Chemical Formula
- C11H11F3N2O3
- Synonyms
- 4'-nitro-3'-trifluoromethylisobutyranilide
- Flutamid
- Flutamida
- Flutamide
- Flutamidum
- FTA
- NFBA
- Niftolid
- Niftolide
- α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidide
- External IDs
- SCH 13521
- SCH-13521
Pharmacology
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Stage b2-c metastatic carcinoma of the prostate •••••••••••• •••••••• •••••• Used in combination to treat Stage d2 metastatic carcinoma of the prostate •••••••••••• •••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Flutamide is a nonsteroidal antiandrogen. In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g. castration. Elevations of plasma testosterone and estradiol levels have been noted following flutamide administration.
- Mechanism of action
Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.
Target Actions Organism AAndrogen receptor antagonistHumans UAryl hydrocarbon receptor agonistHumans UNuclear receptor subfamily 1 group I member 2 Not Available Humans - Absorption
Rapidly and completely absorbed.
- Volume of distribution
Not Available
- Protein binding
94-96%
- Metabolism
Flutamide is rapidly and extensively metabolized, with flutamide comprising only 2.5% of plasma radioactivity 1 hour after administration.
Hover over products below to view reaction partners
- Route of elimination
Flutamide and its metabolites are excreted mainly in the urine with only 4.2% of a single dose excreted in the feces over 72 hours.
- Half-life
The plasma half-life for the alpha-hydroxylated metabolite of flutamide (an active metabolite) is approximately 6 hours.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
In animal studies with flutamide alone, signs of overdose included hypoactivity, piloerection, slow respiration, ataxia, and/or lacrimation, anorexia, tranquilization, emesis, and methemoglobinemia.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Flutamide may decrease the excretion rate of Abacavir which could result in a higher serum level. Abametapir The serum concentration of Flutamide can be increased when it is combined with Abametapir. Abatacept The metabolism of Flutamide can be increased when combined with Abatacept. Abiraterone The serum concentration of Flutamide can be increased when it is combined with Abiraterone. Acalabrutinib The metabolism of Flutamide can be decreased when combined with Acalabrutinib. - Food Interactions
- Take with or without food. The absorption is unaffected by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- International/Other Brands
- Andraxan (CSC) / Antipros (Medicamerc) / Curestat (Advanced Pharmaceutical) / Cytomid (Cipla) / Dedile (Ivax) / Drogenil (Bayer) / Elbat (Genepharm) / Etaconil (Nolver) / Farostat (Orion) / Flimutal (Cryopharma) / Flucinom (Merck Sharp & Dohme) / Flulem (Teva) / Odyne (Nippon Kayaku) / Prostadirex (Sanofi-Aventis) / Prostanon (Pharmachemie)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Euflex Tablet 250 mg Oral Merck Ltd. 1984-12-31 2015-06-01 Canada 
Eulexin Capsule 125 mg/1 Oral Merck Sharp & Dohme Limited 1989-01-27 2005-09-30 US 
Flutamide Tablet 250 mg Oral Aa Pharma Inc 1998-10-08 Not applicable Canada Flutamide Tablet 250 mg Oral Pharmel Inc 1998-12-01 2016-10-25 Canada Flutamide Tablet 250 mg Oral Pharmascience Inc 1997-10-31 2016-10-28 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dom-flutamide Tablet 250 mg / tab Oral Dominion Pharmacal Not applicable Not applicable Canada Eulexin Capsule 125 mg/1 Oral Waylis Therapeutics LLC 2021-11-12 Not applicable US Flutamide Capsule 125 mg/1 Oral Golden State Medical Supply, Inc. 2001-09-18 2023-08-31 US Flutamide Capsule 125 mg/1 Oral Teva 2001-09-19 2018-05-31 US 
Flutamide Capsule 125 mg/1 Oral Physicians Total Care, Inc. 2001-09-18 2004-06-30 US
Categories
- ATC Codes
- L02BB01 — Flutamide
- Drug Categories
- Amides
- Amines
- Androgen Receptor Antagonists
- Androgen Receptor Inhibitors
- Anilides
- Aniline Compounds
- Antiandrogens
- Antiandrogens, non-steroidal
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Antineoplastic and Immunomodulating Agents
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 Substrates
- Drugs that are Mainly Renally Excreted
- Endocrine Therapy
- Hormone Antagonists
- Hormone Antagonists and Related Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Methemoglobinemia Associated Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Trifluoromethylbenzenes
- Direct Parent
- Trifluoromethylbenzenes
- Alternative Parents
- Nitrobenzenes / Anilides / Nitroaromatic compounds / N-arylamides / Secondary carboxylic acid amides / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Organopnictogen compounds / Organofluorides / Organic zwitterions show 4 more
- Substituents
- Alkyl fluoride / Alkyl halide / Allyl-type 1,3-dipolar organic compound / Anilide / Aromatic homomonocyclic compound / C-nitro compound / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Hydrocarbon derivative show 18 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- monocarboxylic acid amide, (trifluoromethyl)benzenes (CHEBI:5132)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 76W6J0943E
- CAS number
- 13311-84-7
- InChI Key
- MKXKFYHWDHIYRV-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
- IUPAC Name
- 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- SMILES
- CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
References
- Synthesis Reference
Jack Lawrence James, Louis Frank Molnar, Jr., Tania E. Toney-Parker, "Processes for preparing flutamide compounds and compounds prepared by such processes." U.S. Patent US 6,228,401, issued November, 1976.
US6228401- General References
- External Links
- Human Metabolome Database
- HMDB0014642
- KEGG Drug
- D00586
- KEGG Compound
- C07653
- PubChem Compound
- 3397
- PubChem Substance
- 46508874
- ChemSpider
- 3280
- BindingDB
- 50131270
- 4508
- ChEBI
- 5132
- ChEMBL
- CHEMBL806
- ZINC
- ZINC000003812944
- Therapeutic Targets Database
- DAP000301
- PharmGKB
- PA449685
- PDBe Ligand
- HFT
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Flutamide
- FDA label
- Download (413 KB)
- MSDS
- Download (55.8 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Congenital Adrenal Hyperplasia (CAH) 1 4 Completed Treatment Premenstrual Syndrome (PMS) 1 4 Completed Treatment Prostate Cancer 1 4 Recruiting Other Androgen Deprivation Therapy / Disorders of the Autonomic Nervous System / Hypertension / Kidney Diseases / Prostate Cancer 1 4 Recruiting Supportive Care Neoplasms of the Prostate 1
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Genpharm inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Par pharmaceutical inc
- Sandoz inc
- Watson laboratories inc
- Packagers
- Barr Pharmaceuticals
- Cipla Ltd.
- Eon Labs
- Ivax Pharmaceuticals
- Neuman Distributors Inc.
- Par Pharmaceuticals
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Salutas Pharma GmbH
- Sandhills Packaging Inc.
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals
- Dosage Forms
Form Route Strength Capsule Oral Tablet Oral Tablet Oral 250 mg Capsule Oral 125 mg/1 Tablet, film coated Oral Tablet, film coated Oral 250 MG Tablet Oral 250 mg / tab Tablet, coated Tablet Oral 250.000 mg - Prices
Unit description Cost Unit Flutamide 125 mg capsule 2.12USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 111.5-112.5 Gold, E.H.; U.S. Patent 3,847,988; November 12, 1974; assigned to Schering Corp. water solubility 9.45 mg/L Not Available logP 3.35 MORRIS,JJ ET AL. (1991) - Predicted Properties
Property Value Source Water Solubility 0.00566 mg/mL ALOGPS logP 2.55 ALOGPS logP 3.27 Chemaxon logS -4.7 ALOGPS pKa (Strongest Acidic) 12.81 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 72.24 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 62.42 m3·mol-1 Chemaxon Polarizability 23.22 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9948 Blood Brain Barrier + 0.9655 Caco-2 permeable + 0.7533 P-glycoprotein substrate Non-substrate 0.8131 P-glycoprotein inhibitor I Non-inhibitor 0.8254 P-glycoprotein inhibitor II Non-inhibitor 0.9428 Renal organic cation transporter Non-inhibitor 0.9535 CYP450 2C9 substrate Non-substrate 0.7927 CYP450 2D6 substrate Non-substrate 0.8935 CYP450 3A4 substrate Substrate 0.568 CYP450 1A2 substrate Inhibitor 0.9108 CYP450 2C9 inhibitor Non-inhibitor 0.6306 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8994 CYP450 3A4 inhibitor Non-inhibitor 0.5924 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6574 Ames test Non AMES toxic 0.5728 Carcinogenicity Carcinogens 0.6077 Biodegradation Not ready biodegradable 0.9924 Rat acute toxicity 2.5770 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9881 hERG inhibition (predictor II) Non-inhibitor 0.8734
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 162.0618379 predictedDarkChem Lite v0.1.0 [M-H]- 152.5649147 predictedDarkChem Lite v0.1.0 [M-H]- 161.15562 predictedDeepCCS 1.0 (2019) [M+H]+ 163.3105379 predictedDarkChem Lite v0.1.0 [M+H]+ 149.7290801 predictedDarkChem Lite v0.1.0 [M+H]+ 163.90152 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.2643379 predictedDarkChem Lite v0.1.0 [M+Na]+ 162.5492379 predictedDarkChem Lite v0.1.0 [M+Na]+ 172.15407 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C: Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11173-7. [Article]
- Martelli A, Campart GB, Carrozzino R, Ghia M, Mattioli F, Mereto E, Orsi P, Puglia CP: Evaluation of flutamide genotoxicity in rats and in primary human hepatocytes. Pharmacol Toxicol. 2000 Mar;86(3):129-34. [Article]
- Montalvo L, Carmena MJ, Solano RM, Clemente C, Roman ID, Sanchez-Chapado M, Prieto JC: Effect of flutamide-induced androgen-receptor blockade on adenylate cyclase activation through G-protein coupled receptors in rat prostate. Cell Signal. 2000 May;12(5):311-6. [Article]
- Pazos F, Sanchez-Franco F, Balsa JA, Escalada J, Palacios N, Cacicedo L: Mechanisms of reduced body growth in the pubertal feminized male rat: unbalanced estrogen and androgen action on the somatotropic axis. Pediatr Res. 2000 Jul;48(1):96-103. [Article]
- Shilling AD, Williams DE: The non-aromatizable androgen, dihydrotestosterone, induces antiestrogenic responses in the rainbow trout. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):187-94. [Article]
- Balk SP: Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Transcription regulatory region dna binding
- Specific Function
- Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
- Gene Name
- AHR
- Uniprot ID
- P35869
- Uniprot Name
- Aryl hydrocarbon receptor
- Molecular Weight
- 96146.705 Da
References
- Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
- Gene Name
- NR1I2
- Uniprot ID
- O75469
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 2
- Molecular Weight
- 49761.245 Da
References
- Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d 24-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A1
- Uniprot ID
- P04798
- Uniprot Name
- Cytochrome P450 1A1
- Molecular Weight
- 58164.815 Da
References
- Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1B1
- Uniprot ID
- Q16678
- Uniprot Name
- Cytochrome P450 1B1
- Molecular Weight
- 60845.33 Da
References
- Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Kang P, Dalvie D, Smith E, Zhou S, Deese A: Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8. doi: 10.1124/dmd.107.014860. Epub 2007 Apr 2. [Article]
- Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [Article]
- Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303. [Article]
- Blobaum AL, Byers FW, Bridges TM, Locuson CW, Conn PJ, Lindsley CW, Daniels JS: A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Drug Metab Dispos. 2015 Nov;43(11):1718-26. doi: 10.1124/dmd.115.064006. Epub 2015 Aug 11. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kang P, Dalvie D, Smith E, Zhou S, Deese A: Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8. doi: 10.1124/dmd.107.014860. Epub 2007 Apr 2. [Article]
- Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
- Gene Name
- ABCC1
- Uniprot ID
- P33527
- Uniprot Name
- Multidrug resistance-associated protein 1
- Molecular Weight
- 171589.5 Da
References
- Grzywacz MJ, Yang JM, Hait WN: Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003 May 15;63(10):2492-8. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:54